NCT06301191View on ClinicalTrials.gov

The Effect of Semaglutide on Cardiovascular Markers and Liver Function

RecruitingOBSERVATIONAL

Enrollment

50

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

March 1, 2023

Study Completion Date

May 1, 2024

Conditions

Diabetes Type 2

Interventions

DRUG

Semaglutide, 1.0 mg/mL

Semaglutide, 1.0 mg/mL

DRUG

Dipeptidyl Peptidase 4 inhibitor

Dipeptidyl Peptidase 4 inhibitor

Trial Locations (1)

12462

RECRUITING

Attikon University General Hospital, Athens

All Listed Sponsors

lead

Attikon Hospital

OTHER